Longevity BioTech Market Report 2026

The longevity biotech market size has grown rapidly in recent years. It will grow from $20.9 billion in 2025 to $23.2 billion in 2026 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to increasing investment in anti-aging research, rising prevalence of age-related chronic diseases, growing interest in extending healthspan, increasing funding from biotech venture capital, and rising adoption of genetic and cellular therapies.

The longevity biotech market size is expected to see rapid growth in the next few years. It will grow to $34.82 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the expansion of regenerative medicine pipelines, rising partnerships between pharma and longevity biotech firms, increasing demand for gene-based therapies, growth of personalized wellness diagnostics, and rising collaboration between research institutes and biotech companies. Major trends in the forecast period include advancement in cellular rejuvenation therapies, advancement in gene-editing technologies, advancement in stem-cell-based regeneration, innovation in senolytic drug development, and innovation in epigenetic reprogramming tools.

The growing emphasis on extending healthy lifespan and preventing age-related decline is expected to drive the growth of the longevity biotech market in the coming years. Healthy aging involves maintaining functional ability, delaying the development of age-related diseases, and supporting physical and mental well-being throughout life. This heightened focus on healthy aging is largely driven by demographic changes, particularly the rapid growth of aging populations, which has increased the demand for medical innovation and preventive healthcare solutions. Longevity biotechnology supports this objective by developing therapies, diagnostics, and preventive strategies that target the biological processes of aging, strengthen cellular resilience, and lower the risk of age-related disorders. For example, in November 2023, according to the World Health Organization, a Geneva-based global health authority, the global population aged 60 years and older is expected to rise from 1.1 billion in 2023 to 1.4 billion by 2030 and reach 2.1 billion by 2050, underscoring the growing scale of aging-related health challenges. As a result, the increasing global focus on healthy lifespan extension and aging prevention is contributing to the expansion of the longevity biotech market.

Major companies operating in the longevity biotech market are focusing on developing biological-age diagnostics, such as DNA methylation-based epigenetic Index tests, to quantify biological age and system-specific aging rates. Epigenetic Index tests analyze DNA methylation patterns at CpG sites to generate an estimate of biological age, which companies use as an outcome measure for product development, clinical validation, and consumer feedback. These diagnostics enable more precise monitoring of aging processes and assessment of intervention effectiveness. For instance, in March 2023, Elysium Health, a US-based life-science company, introduced the TIME-A longitudinal research study linked to its Index epigenetic test. The initiative enrolls Index users, integrates survey and epigenetic data for longitudinal aging analysis, and provides participants with system-level biological-age insights, supporting data-driven advancement in longevity research and personalized health optimization.

In June 2025, Juvenescence Limited, an Isle of Man-based clinical-stage AI-enabled biotechnology company, acquired Ro5 Inc. for an undisclosed amount. Through this acquisition, Juvenescence aims to strengthen its drug discovery capabilities by integrating Ro5’s advanced artificial intelligence platform, enabling faster identification and optimization of therapeutic candidates targeting age-related diseases. Ro5 Inc. is a US-based company specializing in AI-driven drug discovery technologies that analyze complex biological datasets to uncover novel compounds and accelerate early-stage therapeutic development.

Major companies operating in the longevity biotech market are Insilico Medicine Inc., Calico Life Sciences LLC, Retro Biosciences Inc., Altos Labs Inc., LyGenesis Inc., NewLimit Inc., Halia Therapeutics Inc., Life Biosciences Inc., BioAge Labs Inc., Rubedo Life Sciences Inc., Juvenescence Limited, Cambrian BioPharma Inc., Elevian Inc., Oisin Biotechnologies Inc., Rejuvenate Bio Inc., Unity Biotechnology Inc., Cleara Biotech B.V., Junevity Inc., Liv Longevity Labs, Genflow Biosciences plc, Centenara Labs AG.

North America was the largest region in the longevity biotech market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the longevity biotech market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the longevity biotech market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Tariffs are influencing the longevity biotech market by increasing costs of imported laboratory instruments, sequencing equipment, bioreactors, and specialized research reagents. research institutes and biotech firms in north america and europe are most affected due to reliance on imported high-precision tools, while asia-pacific faces cost pressures in equipment procurement. these tariffs are increasing research and development expenses and extending project timelines. however, they are also encouraging domestic biotech manufacturing, regional equipment sourcing, and localized innovation ecosystems.

Longevity biotech is a sector dedicated to creating biological innovations that slow the aging process, prevent age-related deterioration, and extend healthy human lifespan. It leverages advanced approaches such as genetics, cellular engineering, and AI-driven discovery to identify and target the underlying mechanisms of aging. The field aims to develop therapies and technologies that preserve health and functional capacity for a longer portion of life.

The primary services in longevity biotech include longevity consultation, biological age testing, preventive health programs, and other specialized services. Longevity consultation involves personalized scientific evaluation of aging, genetics, lifestyle, and risk factors to design tailored health strategies. Therapeutic approaches include senolytics, gene therapy, regenerative medicine, metabolic modulators, and mitochondrial therapies. Technologies involve gene editing, AI/ML, stem-cell platforms, multi-omics tools, and advanced screening. Applications span healthcare, biotechnology, pharmaceuticals, wellness, and aging populations, serving clinics, hospitals, research institutes, and direct-to-consumer clients.

The longevity biotech consists of revenues earned by entities by providing services such as biomarker testing, genetic testing, diagnostic screening, longevity coaching, personalized health assessment, clinical research services, data analytics services, telehealth monitoring, laboratory analysis, and preventive healthcare consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. Longevity biotech also includes sales of therapeutic drugs, gene therapy kits, diagnostic devices, wearable health trackers, laboratory testing kits, nutraceutical formulations, and cellular therapy materials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.